List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 36 studies with search of: "Valganciclovir"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: valganciclovir [Valcyte];   Drug: valganciclovir [Valcyte]
2 Active, not recruiting Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Condition: Cytomegalovirus Infections
Interventions: Drug: valganciclovir;   Drug: valganciclovir
3 Completed Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Condition: Cytomegalovirus Infection
Intervention: Drug: Single arm (ganciclovir and valganciclovir)
4 Active, not recruiting Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Condition: Chronic Fatigue Syndrome
Intervention: Drug: valganciclovir
5 Withdrawn Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
Condition: Giant Lymph Node Hyperplasia
Intervention: Drug: Valganciclovir
6 Completed A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Condition: Cytomegalovirus Infections
Intervention: Drug: valganciclovir [Valcyte]
7 Active, not recruiting Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
Conditions: Glioblastoma Multiforme;   Cytomegalovirus Infection
Intervention: Drug: Valganciclovir (Valcyte)
8 Terminated WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients
Condition: Kidney Transplant
Intervention: Drug: Valganciclovir
9 Active, not recruiting A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Condition: Cytomegalovirus Infections
Interventions: Drug: valganciclovir [Valcyte];   Drug: Pre-emptive therapy
10 Completed A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Condition: Cytomegalovirus Infections
Intervention: Drug: valganciclovir [Valcyte]
11 Completed Suppression of Oral HHV8 Shedding With Valganciclovir
Condition: Human Herpesvirus 8
Interventions: Drug: valganciclovir;   Drug: placebo
12 Completed VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: valganciclovir [Valcyte];   Drug: Ganciclovir
13 Completed Oral Valganciclovir Versus Valacyclovir
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Valganciclovir;   Drug: Valacyclovir
14 Recruiting Pharmacokinetics of Mmf and Valganciclovir
Conditions: Kidney Transplant Recipient;   Heart Transplant Recipient
Interventions: Drug: Mycophenolate mofetil;   Drug: Valganciclovir
15 Completed Study of Prophylactic Vs Preemptive Valganciclovir
Condition: Cytomegalovirus Infection
Intervention: Drug: Valganciclovir
16 Active, not recruiting Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
Conditions: Cytomegalovirus Retinitis;   HIV Infections
Intervention: Drug: Valganciclovir
17 Completed Valganciclovir in Congenital CMV Infants
Condition: Cytomegalovirus Infections
Interventions: Drug: Ganciclovir;   Drug: Valganciclovir
18 Terminated MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
Conditions: Cytomegalovirus Infections;   Inflammatory Bowel Diseases
Intervention: Drug: Valganciclovir
19 Recruiting Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Condition: Cytomegalovirus Infections
Interventions: Drug: Placebo;   Drug: Valganciclovir
20 Recruiting Valganciclovir to Reduce T Cell Activation in HIV Infection
Conditions: HIV Infections;   Cytomegalovirus Infections
Intervention: Drug: valganciclovir 900mg daily vs. placebo x 8 weeks

Previous Page Studies Shown (1-20) Next Page (21-36)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services